What's Next for Cremascoli Ortho?
One of the few mid-sized European orthopedic companies to build a continental presence, Cremascoli has been extremely successful. But now it contemplates its future in an industry driven by consolidation.
You may also be interested in...
Long a pioneer in prosthetics, one of orthopedics' forgotten spaces, Stanmore Implants Worldwide, has a new investor group who hope to transform this once academic supplier into a thriving orthopedics player by focusing on specialty niches that the Ortho giants have largely ignored.
Phase I data presented at ASCO for ALLO-501 offer proof of concept for the CD19 allogeneic CAR-T and a companion drug, ALLO-647, for lymphodepletion.